Sign in to view content

Baseline Characteristics of Patients Who Did or Did Not Maintain 12-Week and 16-Week Aflibercept 8 mg Dosing Intervals in the Phase 2/3 PHOTON Trial

Eric W Schneider, MD

Video
Published 2023

Related

Response to Ranibizumab of Eyes With Pigment Epithelial Detachments, Including Eyes That Developed RPE Tears: Data From the HARBOR Study
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2016
Interaction of Genotypes and AREDS Formulation Use in the Development of Neovascular AMD
Pradeepa Yoganathan, MSc, MD, FRCS(C)
Annual Meeting Talks
2019
Intravitreal Aflibercept 8 mg Injection in Patients With Neovascular Age-Related Macular Degeneration: 48-week Results From the Phase 3 PULSAR Trial
Jignesh I Patel, MD FRCOphth
Annual Meeting Talks
2023

Category: Diabetic Retinopathy

See more